April 5, 2023 07:05 AM EDTUpdated 08:42 AM
People

Fol­low­ing clin­i­cal set­backs, NGM Bio lays off 33% of staffers as founder de­parts

Amber Tong

NGM Bio hint­ed at fi­nan­cial strain at the end of Feb­ru­ary when it an­nounced 2022 fi­nan­cial re­sults, not­ing a nar­rowed fo­cus on on­col­o­gy and an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A look at biotech's year of the megaround

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

A service from the Financial Times